13 Oct 2026
Breast Cancer Advocates Call for $6.9 Million to Improve Metastatic Cancer Data
Breast Cancer Network Australia (BCNA) is urging the Australian Government to invest $6.913 million over four years in a national cancer data system to improve recognition and support for people living with metastatic breast cancer.
08 Oct 2026
Australians Gain New Protection Against Genetic Discrimination
Australians can now access genetic testing without the same concerns about its impact on their life insurance, following the introduction of new legal protections.
14 Jul 2026
BCNA Highlights the Power of Lived Experience at Global Cancer Care Conference
Breast Cancer Network Australia (BCNA) played a key role at the 2026 MASCC/ISOO Annual Meeting, held in Melbourne from 25–27 June.
10 Jul 2026
BCNA Builds Stronger Partnerships for First Peoples Breast Cancer Care
Leaders from the Breast Cancer Network Australia (BCNA) have visited Palm Island to hear directly from Aboriginal and Torres Strait Islander community members about their experiences with breast cancer care and to better understand how healthcare services can become more culturally responsive.
01 Jul 2026
PBS Listing Expands Access to Perjeta for Australians with Early Breast Cancer
From 1 July 2026, Perjeta (pertuzumab) is available on the Pharmaceutical Benefits Scheme (PBS) for eligible Australians with HER2-positive high-risk early breast cancer, making the treatment more affordable for thousands of patients.
25 May 2026
New Data Shines Light on Australians Living with Metastatic Breast Cancer
One year after an international pledge to improve recognition of metastatic breast cancer, Australia has achieved a major milestone with the release of the country's first national estimate of people living with the disease.
13 May 2026
Australia’s metastatic breast cancer data gains global attention at major conference
Australia’s approach to counting people living with metastatic breast cancer was highlighted at one of the world’s leading cancer conferences, held by the European Society for Medical Oncology (ESMO) in Berlin.
07 May 2026
Update on Zoladex treatment access for people with breast cancer
Breast Cancer Network Australia (BCNA) has confirmed it is seeking more information after AstraZeneca announced it will discontinue the Zoladex (goserelin) 3.6mg implant in Australia from 1 November 2026.
29 Sep 2025
Capivasertib (Truqap) Now Accessible on PBS for Metastatic Breast Cancer Patients
The Australian Government has recently listed capivasertib (Truqap) on the Pharmaceutical Benefits Scheme (PBS), providing an important new treatment option for people living with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC).
10 Jul 2025
Count Us In. From Australia to the world: Leading the push for global metastatic breast cancer visibility
Count Us In. From Australia to the world: Leading the push for global metastatic breast cancer visibility